In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aegera Therapeutics Inc.

Division of Pharmascience Inc.
www.aegera.com

Latest From Aegera Therapeutics Inc.

Sizing Up The Competition In BTK Inhibition

Celgene’s latest Phase I dose-ranging data for the BTK inhibitor CC-292 show better response rates than before. The BTK target has become highly attractive, yet the competitive landscape for this particular class still looks sparse, with four drugs in the clinic and two slated for INDs in 2014.

BioPharmaceutical Clinical Trials

Death list: Round-up of deals that died in December

While there was a flurry of new deal agreements and completed acquisitions last month, several partnerships died a death. According to Medtrack data, seven pharma/biotech agreements were terminated during December, including some that had once been flagged as potential nine- or ten-figure money-spinners.

Metabolic Disorders Immune Disorders

Deals Shaping the Medical Industry (06/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

After Benlysta win, HGSI expands cancer pipeline with FivePrime deal

A week after successfully winning US approval of its lupus drug Benlysta (belimumab), Human Genome Sciences is stepping up its game in the cancer therapy arena by adding a new asset to its development pipeline through a deal with FivePrime Therapeutics, which has licensed the US, Canadian and European Union rights to HGSI for FP-1039, a fibroblast growth factor (FGF) ligand trap under investigation for a variety of cancers (scripintelligence, 10 March 2011).

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • Apoptogen
  • Exogen Neurosciences
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Pharmascience Inc.
  • Senior Management
  • Donald Olds, COO & CFO
    John Gillard, PhD, EVP, CSO
  • Contact Info
  • Aegera Therapeutics Inc.
    Phone: (514) 288-5532
    810 Chemin du Golf
    Montreal, H3E 1A8
    Canada
UsernamePublicRestriction

Register